Feifan Tang
Monterey Park, CANPI 1568150035
Payments from drug & device makers
Across 204 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$687
- Bayer$538
- Ardelyx, Inc.$480
- Regeneron Healthcare Solutions, Inc.$474
- Lilly USA, LLC$356
- Phathom Pharmaceuticals, Inc.$346
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $687 |
| Bayer | 20 | $538 |
| Ardelyx, Inc. | 21 | $480 |
| Regeneron Healthcare Solutions, Inc. | 17 | $474 |
| Lilly USA, LLC | 14 | $356 |
| Phathom Pharmaceuticals, Inc. | 18 | $346 |
| Amgen | 11 | $307 |
| GSK | 10 | $231 |
| Boehringer Ingelheim | 6 | $195 |
| Axsome Therapeutics, Inc. | 4 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $147 |
| Pfizer | 6 | $142 |
| Sanofi | 3 | $135 |
| Merck | 5 | $123 |
| Madrigal Pharmaceuticals | 5 | $121 |
| Radius Health, Inc. | 5 | $115 |
| AbbVie | 5 | $95 |
| Lexicon Pharmaceuticals, Inc. | 3 | $93 |
| Sun Pharmaceutical Industries Inc. | 4 | $91 |
| Corcept Therapeutics | 3 | $57 |
| Oyster Point Pharma, Inc. | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Alk-abello, Inc | 2 | $44 |
| Johnson & Johnson | 2 | $43 |
| Novo Nordisk | 2 | $42 |
| Gilead | 2 | $40 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Vivus LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 295 | $113,044 |
| CreonLipase/Protease/Amylase | 36 | $77,590 |
| FarxigaDapagliflozin Propanediol | 111 | $72,393 |
| ProliaDenosumab | 40 | $67,325 |
| KerendiaFinerenone | 75 | $51,779 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 19 | $46,060 |
| JanuviaSitagliptin Phosphate | 61 | $44,729 |
| JardianceEmpagliflozin | 60 | $43,159 |
| LinzessLinaclotide | 73 | $40,751 |
| RybelsusSemaglutide | 36 | $40,556 |
| Xigduo XrDapaglifloz Propaned/Metformin | 64 | $40,171 |
| OzempicSemaglutide | 34 | $39,190 |
| EliquisApixaban | 56 | $38,578 |
| RestasisCyclosporine | 39 | $27,876 |
| VemlidyTenofovir Alafenamide | 14 | $23,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $95 | $146,217148 claims |
| AmgenProlia, Evenity (2 Syringes) | $307 | $113,38459 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $687 | $84,280130 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $195 | $81,509120 claims |
| Novo NordiskRybelsus, Ozempic | $42 | $79,74770 claims |
| MerckJanuvia, Janumet, Janumet Xr | $123 | $74,596116 claims |
| PfizerEliquis, Nurtec Odt | $142 | $52,31568 claims |
| BayerKerendia | $538 | $51,77975 claims |
| GSKTrelegy Ellipta, Havrix | $231 | $25,70497 claims |
| GileadVemlidy | $40 | $23,14314 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $346 | $19,50926 claims |
| Johnson & JohnsonXarelto | $43 | $9,34414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.